Unbiased comparison of sample size estimates from longitudinal structural measures in ADNI
Open Access
- 9 August 2011
- journal article
- research article
- Published by Wiley in Human Brain Mapping
- Vol. 33 (11), 2586-2602
- https://doi.org/10.1002/hbm.21386
Abstract
Structural changes in neuroanatomical subregions can be measured using serial magnetic resonance imaging scans, and provide powerful biomarkers for detecting and monitoring Alzheimer's disease. The Alzheimer's Disease Neuroimaging Initiative (ADNI) has made a large database of longitudinal scans available, with one of its primary goals being to explore the utility of structural change measures for assessing treatment effects in clinical trials of putative disease‐modifying therapies. Several ADNI‐funded research laboratories have calculated such measures from the ADNI database and made their results publicly available. Here, using sample size estimates, we present a comparative analysis of the overall results that come from the application of each laboratory's extensive processing stream to the ADNI database. Obtaining accurate measures of change requires correcting for potential bias due to the measurement methods themselves; and obtaining realistic sample size estimates for treatment response, based on longitudinal imaging measures from natural history studies such as ADNI, requires calibrating measured change in patient cohorts with respect to longitudinal anatomical changes inherent to normal aging. We present results showing that significant longitudinal change is present in healthy control subjects who test negative for amyloid‐β pathology. Therefore, sample size estimates as commonly reported from power calculations based on total structural change in patients, rather than change in patients relative to change in healthy controls, are likely to be unrealistically low for treatments targeting amyloid‐related pathology. Of all the measures publicly available in ADNI, thinning of the entorhinal cortex quantified with the Quarc methodology provides the most powerful change biomarker. Hum Brain Mapp, 2012.Keywords
This publication has 89 references indexed in Scilit:
- Nonlinear registration of longitudinal images and measurement of change in regions of interestMedical Image Analysis, 2011
- Reduced sample sizes for atrophy outcomes in Alzheimer's disease trials: baseline adjustmentNeurobiology of Aging, 2010
- Integrating ADNI results into Alzheimer's disease drug development programsNeurobiology of Aging, 2010
- Comparing 3 T and 1.5 T MRI for tracking Alzheimer's disease progression with tensor‐based morphometryHuman Brain Mapping, 2010
- APOE predicts amyloid‐beta but not tau Alzheimer pathology in cognitively normal agingAnnals of Neurology, 2010
- Cerebrospinal fluid tau and ptau 181 increase with cortical amyloid deposition in cognitively normal individuals: Implications for future clinical trials of Alzheimer's diseaseEMBO Molecular Medicine, 2009
- Comparing registration methods for mapping brain change using tensor-based morphometryMedical Image Analysis, 2009
- Neuropathology of nondemented aging: Presumptive evidence for preclinical Alzheimer diseaseNeurobiology of Aging, 2009
- Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjectsAnnals of Neurology, 2009
- Cortical Surface-Based Analysis: I. Segmentation and Surface ReconstructionNeuroImage, 1999